Celldex Therapeutics Profile

USD 0.0042  0.81%

Sale by Harry Penner of 17728 shares of Celldex Therapeutics

Celldex Therapeutics insider trading alert for sale of common stock by Harry Penner, the corporate stakeholder, on July 18, 2018. This event was filed by Celldex Therapeutics Inc with SEC on 2013-12-10. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Celldex Therapeutics Summary

Celldex Therapeutics (CLDX) is traded on BATS Exchange in USA. It is located in NEW JERSEY U.S.A and employs 192 people. Celldex Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with current market capitalization of 74.39 M. Celldex Therapeutics conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 143.39 M outstanding shares of which 8.65 M shares are currently shorted by private and institutional investors with about 2.76 trading days to cover. CELLDEX THERAPEUT currently holds about 123.25 M in cash with (92.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Celldex Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 0.5158HorizonTargetOdds Above 0.5158
45.25%30 days 0.52 54.44%
Based on normal probability distribution, the odds of Celldex Therapeutics to move above current price in 30 days from now is about 54.44% (This Celldex Therapeutics probability density function shows the probability of Celldex Therapeutics Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Meditor Group LtdCommon Shares6.3 M3.2 M
Creative PlanningCommon Shares15.2 K8 K
View Celldex Therapeutics Diagnostics

Selected Celldex Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Celldex Therapeutics Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Celldex Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc. Rockefeller University University of Southampton Amgen Inc. Amgen Fremont Seattle Genetics, Inc. Yale University and MedImmune, LLC. Celldex Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 192 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Celldex Therapeutics SEC Filings
Celldex Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameCelldex Therapeutics
President CEO, DirectorAnthony MarucciView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business AddressPerryville III Building
ExchangeBATS Exchange
CIK Number0000744218
IndustryPharmaceutical Products
Phone908 200 7500
CurrencyUSD - US Dollar

Celldex Therapeutics Corporate Directors

Keith Brownlie Director
Harry Penner Independent Director
Karen Shoos Independent Director
Check also Trending Equities. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.